Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sarepta Therapeutics
Pharma
Sarepta extends $700M debt to 2030 amid Elevidys uncertainty
The debt refinancing and private placement represent Sarepta's latest move in a series of intensive measures to improve its financial position.
Angus Liu
Aug 21, 2025 10:52am
Sarepta shares more Elevidys safety data
Aug 18, 2025 11:32am
Vinay Prasad is back at the FDA after last month's surprise ouster
Aug 9, 2025 12:22pm
With $1B in debts due in 2027, Sarepta weighs efficiency measures
Aug 6, 2025 5:44pm
Untangling Sarepta’s gene therapy fallout
Aug 1, 2025 9:07am
Prasad exit signals more permissive FDA for cell and gene field
Jul 31, 2025 9:10am
